Scott Bright, PhD
Department of Radiation Physics, Division of Radiation Oncology
Present Title & Affiliation
Primary Appointment
Assistant Professor, Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professsor, Radiation Physics - Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
Research Interests
Through an integrated program spanning conventional radiotherapy, DNA repair, cancer metabolism, mitochondrial signaling, immuno-oncology, and radiopharmaceutical development, my research seeks to define and exploit tumor-specific vulnerabilities to improve the precision and durability of radiotherapy. By combining mechanistic discovery with translational application, I aim to develop rational, biology-driven treatment strategies that maximize tumor control while minimizing normal tissue toxicity.
Education & Training
Degree-Granting Education
| 2014 | Oxford Brookes University, Oxford, GB, Ph.D. in Cell/Molecular Biology |
| 2009 | Oxford Brookes University, Oxford, GB, BS in Biomedical Science |
Postgraduate Training
| 2017-2021 | Postdoctoral Fellow, Photon and Proton Radiotherapy, The University of Texas MD Anderson, Houston, Texas |
| 2014-2017 | Postdoctoral Fellow, Exosome Signaling in Radiation Response, Oxford Brookes University, Oxford |
Experience & Service
Faculty Academic Appointments
Instructor, Radiation Physics - Research, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2021 - 2024
Intramural Institutional Committee Activities
Student representative, Research degree sub-committee, Oxford Brookes University, 2012 - 2013
Extramural Institutional Committee Activities
Member, Website and education committee, Radiation Research society, 2022 - Present
Honors & Awards
| 2025 | AACR Translational Cancer Research Workshop, AACR |
| 2025 | High scoring abstract, American Association of Physicists in Medicine (AAPM) |
| 2025 | Early career investigator travel award, Radiation Research society |
| 2024 | Early career investigator travel award, Radiation Research society |
| 2023 | Early Career Investigator travel award, Radiation Research/International Congress for Radiation Research |
| 2021 | Farrington Daniels Award, American Association of Physicists in Medicine (AAPM) |
| 2018 | Science Highlights Award, American Association of Physicists in Medicine (AAPM) |
| 2017 | SIT Travel Award, Radiation Research Society |
| 2016 | Newton Award, The Royal Society |
| 2015 | DoReMi Travel Award, European Atomic Energy Community |
| 2011 | NASA Space Radiation Summer School Fellowship, NASA |
| 2009 | President's Prize, Institute of Biomedical Science |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Glutaminase 1 inhibition sensitizes radioresistant KEAP1 mutant lung cancer cell lines to protons. Invited. Houston, Texas, US.
Regional Presentations
- 2022. Targeting Glutaminase for radiosensitization with the small molecule inhibitor IACS-6274. Conference. Southwest Regional Chapter of American Association of Physicists in Medicine. Galveston, TX, US.
- 2017. Does DNA double strand break repair deficiency play a role in the sensitivity of cells to therapeutic proton beams?. Conference. CPRIT Innovations In Cancer Prevention and Research Conference. Houston, TX, US.
- 2014. Extracellular Vesicles and Their Role in Radiation Induced Cellular Effects. Conference. Oxford, Oxford, GB.
National Presentations
- 2025. Inhibition of Metabolism Radiosensitizes Lung Cancer Cells to Photons and Protons. Poster. AAPM Annual meeting, US.
- 2024. A small molecule inhibitor targeting Glutaminase-1 radiosensitizes lung cancer cell lines through metabolic disruption. Conference. AAPM Annual meeting. Los Angeles, California, US.
- 2024. Experience and Grantsmanship with AAPM Seed Grant. Invited. AAPM Annual meeting. Los Angeles, California, US.
- 2024. Modulating mitochondria metabolism to radiosensitize KEAP1 mutated non-small cell lung cancer. Poster. AACR DNA Damage Repair: From Basic Science to Future Clinical Application. Washington, DC, US.
- 2023. Targeting Glutaminase for radiosensitization with the small molecule inhibitor IACS-6274. Conference. AAPM Annual meeting. Houston, TX, US.
- 2022. Biological Optimization of Proton Radiotherapy Through Glutaminase 1 Inhibition. Conference. AAPM Annual meeting. Washington, D.C, US.
- 2021. DNA Damage Response Inhibitors of DNA-PKcs, PARP, RAD51, ATR and ATM All Sensitize Cancer Cells to X-rays and Protons - Poster Presentation. Conference. ASTRO Annual meeting. Chicago, IL, US.
- 2021. Inhibiting ATR Modulates Response to Radiation and Stimulates Immune Responses. Conference. ASTRO Annual meeting. Chicago, IL, US.
- 2021. A Physics Approach to Combine Radiotherapy with Moleculary Targeted Therapies to Preferentially Radiosensitize Tumors But Not Normal Tissues. Conference. AAPM Annual meeting.
- 2021. A DNA Repair Inhibitor Targeting ATR Modulates Immune Responses to Radiotherapy. Conference. AAPM Annual meeting.
- 2019. The Non-Homologous End Joining Repair Pathway Determines Cell Radiosensitivity in Helium and Carbon Ion Beams. Conference. AAPM Annual meeting. San Antonio, TX, US.
- 2018. Linking Single-Site DNA Damage Response to Individual Charged Particle Type in C-Ion Radiotherapy Beams. Conference. AAPM Annual meeting. Nashville, TN, US.
- 2018. Role of Double Strand Break DNA Repair Deficiency on the Sensitivity of Cells to Therapeutic Proton Beams. Conference. AAPM Annual meeting. Nashville, TN, US.
- 2018. The Importance of DNA Double Strand Break Repair Defects to Cell Radiosensitivity in Helium and Carbon Ion Beams. Conference. AAPM Annual meeting. Nashville, TN, US.
- 2016. Radiation Induced Cataracts: Recent Mechanistic Developments and Research Gaps. Conference. Radiation protection week. Oxford, GB.
- 2016. Role of Microvesicles/Exosomes and the Epigenetic Cargo in Non-Targeted Effects of Radiation: An in vivo Study. Conference. Radiation protection week. Oxford, GB.
- 2016. Low-Dose Ionizing Radiation-Induced Cataracts in the Mouse – A Lifetime Study. Conference. Radiation protection week. Oxford, Oxford, GB.
- 2010. Identifying Molecular Signalling Communication Between Irradiated Cells and Their Microenvironment. Conference. Association for Radiation Research annual meeting. Oxford, Oxford, GB.
International Presentations
- 2026. Inhibiting glutamine metabolism in combination with radiation disrupts mitochondrial function and impairs homologous recombination. Poster. AACR Annual meeting.
- 2025. Glutaminase-1 inhibition disrupts mitochondrial function and integrity contributing to radiosensization in KEAP1 mutant lung cancers. Poster. RRS Annual meeting, US.
- 2025. Disruption of glutamine metabolism differently radiosensitizes protons vs photons in KEAP1 mutated lung cancer cell lines. Conference. PTCOG annual meeting, AR.
- 2024. Glutaminase-1 inhibition leads to excessive mitochondrial ROS production and radiosensitization. Conference. RRS annual meeting. Tucson, US.
- 2024. DNA damage and repair. Invited. Advanced Course on Biomedical Imaging. Online, PT.
- 2023. Glutaminase-1 inhibition radiosensitizes lung cancer cells to photons and protons through metabolic disruption and oxidative stress. Conference. ICRR 2023. Montreal, CA.
- 2023. Glutaminase 1 inhibition sensitizes radioresistant KEAP1 mutant lung cancer cell lines to protons. Conference. PTCOG annual meeting. Madrid, ES.
- 2022. Inhibition of Glutaminase-1 (GLS1) sensitizes KEAP1 mutant lung cancer cell lines to photons and protons. Conference. RRS annual meeting. Kailua-Kona, US.
- 2022. Inhibition of Glutaminase-1 (GLS1) increases the relative biological effectiveness of proton radiotherapy and increases levels of lipid peroxidation. Conference. PTCOG Annual meeting. Miami, US.
- 2021. A DNA Repair Inhibitor Targeting ATR Modulates Immune Responses to Radiotherapy - Poster Presentation. Conference. RRS annual meeting.
- 2021. Glutaminase Inhibition Radiosensitizes Non-Small Cell Lung Cancer Cells to X-rays and Protons. Conference. RRS annual meeting.
- 2021. DNA repair inhibitors modulate cancer cell survival to photons and protons. Conference. PTCOG annual meeting.
- 2020. The ATR Inhibitor, AZD6738, Sensitizes Cells to Radiation and More So for Protons. Conference. RRS annual meeting.
- 2019. DNA Damage Repair Inhibition is More Important Than Proton LET in Dictating Cell Survival. Conference. RRS annual meeting. San Diego, US.
- 2018. Role of double strand break DNA repair deficiency on the sensitivity of cells to therapeutic proton beams. Conference. RRS annual meeting. Chicago, US.
- 2017. Low Dose Response to Ionising Radiation and its Role in Cataractogenesis. Conference. RRS annual meeting. Cancun, MX.
- 2017. Role of Exosomes and Their Epigenetic Cargo in Non-Targeted Effects (NTE) of Radiation: in vivo Study. Conference. RRS annual meeting. Cancun, MX.
- 2015. Radiation Exposure and Lens Opacities. Conference. DoReMi. Budapest, HU.
- 2015. X-rays Damage Human Lens Epithelial Cells in A Genotype and Dose Dependent Manner - Poster Presentation. Conference. ICRR 2015. Kyoto, JP.
- 2014. The Future Impacts of Radiation Induced Non-Targeted Effects. Invited. RRS annual meeting. Las Vegas, US.
- 2012. Radiation Induced Sub-Cellular Alterations and Potential for Non-Targeted Effects. Conference. International Systems Biology Workshop (IRSB). Oxford, GB.
- 2011. Lysosomal Stability is Altered in Response to Ionizing Radiation. Conference. ICRR 2011. Warsaw, PL.
Grant & Contract Support
| Date: | 2027 - 2029 |
| Title: | Improving radionuclide therapuetic efficacy through inhibition of pathways contributing to radioresistance |
| Funding Source: | NIH |
| Role: | PI |
| Date: | 2026 - 2029 |
| Title: | The integrated stress response as a mediator of resistance to glutamine metabolism inhibition |
| Funding Source: | CPRIT |
| Role: | PI |
| Date: | 2026 - 2028 |
| Title: | In Vivo evaluation of the metabolic inhibitor IACS-6274 in combination with radiotherapy |
| Funding Source: | NIH |
| Role: | PI |
| Date: | 2026 - 2031 |
| Title: | Radionuclide Theranostics Targeting MUC13 for Pancreatic Cancer |
| Funding Source: | NIH |
| Role: | Co-I |
| Date: | 2026 - 2029 |
| Title: | Targeting tumor-specific nutrient stress responses in pancreatic cancer |
| Funding Source: | AACR |
| Role: | PI |
| Date: | 2026 - 2031 |
| Title: | Exploiting mitochondrial retrograde signaling in KEAP1 mutant NSCLC |
| Funding Source: | NIH |
| Role: | PI |
| ID: | 1R01CA311754-01 |
| Date: | 2026 - 2028 |
| Title: | Improving radionuclide therapuetic efficacy through inhibition of pathways contributing to radioresistance |
| Funding Source: | NIH |
| Role: | PI |
| Date: | 2025 - 2028 |
| Title: | Targeting mitochondrial retrograde signaling for radiosensitization in KEAP1 mutant lung cancers |
| Funding Source: | CPRIT |
| Role: | PI |
| ID: | RP260306 |
| Date: | 2025 - 2027 |
| Title: | Using nanomechanical signatures to predict lung cancer response to radiotherapy in combination with PARP inhibition |
| Funding Source: | ARTIDIS |
| Role: | PI |
| Date: | 2025 - 2026 |
| Title: | Improving Radionuclide Therapeutic Efficacy through Inhibition of Pathways Contributing to Radioresistance |
| Funding Source: | The U Foundation |
| Role: | PI |
| Date: | 2024 - Present |
| Title: | Targeting glutamine metabolism to sensitize KEAP1 mutated lung cancer to radiotherapy |
| Funding Source: | DoD |
| Role: | Co-I |
| Date: | 2024 - 2026 |
| Title: | Combination of radiation and pharmacological disruption of metabolism for immunosensitization in lung cancer |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2024 - Present |
| Title: | Inhibition of DNA polymerase theta for increased tumor radiosensitization and radiation induced immunogenicity |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2024 - Present |
| Title: | Targeting glutamine metabolism with glutaminase 1 inhibition to radiosensitize lung cancer |
| Funding Source: | CPRIT |
| Role: | PI |
| Date: | 2024 - Present |
| Title: | Sensitizing immunologically cold tumors to immunotherapy using proton therapy in combination with ATR inhibition |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Date: | 2024 - Present |
| Title: | Combining proton therapy with ATR inhibition to sensitize immunologically cold tumors to immune checkpoint blockade |
| Funding Source: | CPRIT |
| Role: | Co-I |
| Date: | 2024 - Present |
| Title: | Combating immunotherapy resistance in metastatic breast cancer using alpha particles and PARP1 inhibition |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2024 - Present |
| Title: | Targeting glutamine metabolism with glutaminase 1 inhibition to radiosensitize lung cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2023 - Present |
| Title: | Targeting Glutaminase 1 in combination with proton therapy to sensitize KEAP1 mutant tumors: mechanisms and pre-clinical translation |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Date: | 2023 - 2024 |
| Title: | Exploiting inhibition of microhomology-mediated end joining for selective radio sensitization of tumors |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
| Date: | 2023 - 2028 |
| Title: | Alpha particles combined with ATR inhibition to activate the immune system: mechanisms and pre-clinical translation |
| Funding Source: | NIH/STRIPE |
| Role: | Co-I |
| Date: | 2023 - 2025 |
| Title: | Diffusing alpha-emitters radiation therapy (DaRT) combined with ATR inhibition for antitumor immune activation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2023 - 2024 |
| Title: | Radiation Sensitization via Pharmacological Disruption of Glutamine Transport |
| Funding Source: | MD Anderson - CCSG Imaging-Driven Biology and Therapeutics |
| Role: | Co-PI |
| Date: | 2023 - 2025 |
| Title: | Modulating metabolism to sensitize lung tumors to proton therapy |
| Funding Source: | Department of Defense - LCRP |
| Role: | Co-I |
| ID: | LC220177 |
| Date: | 2022 - 2024 |
| Title: | Potentiation of ferroptosis by glutaminase inhibition combined with proton radiotherapy to augment anti-tumor immune responses |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2022 - 2023 |
| Title: | Modulating a Metabolic Pathway to Amplify the Relative Biological Effectiveness of Proton Therapy |
| Funding Source: | American Association of Physicists in Medicine (AAPM) |
| Role: | PI |
| Date: | 2022 - 2023 |
| Title: | DaRT in Combination with Inhibitors of PARP and PD-L1 to Enhance Immune Stimulation |
| Funding Source: | Alpha Tau Medical |
| Role: | Co-I |
| Date: | 2022 - 2022 |
| Title: | Pre-clinical Assessment of ART0380 and ART4215 Combined with X-rays and Protons for Radiosensitization and Immune Stimulation |
| Funding Source: | Artios Pharma |
| Role: | Co-I |
| Date: | 2021 - 2022 |
| Title: | Amplification of Immune Stimulation by Using Diffusing Alpha-Emitters Radiation Therapy (DaRT) and ATR Inhibition |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
| Title: | MUC13-Targeted Terbium-161 Radiopharmaceutical Therapy for Pancreatic Cancer |
| Funding Source: | United States Department of Defense |
| Role: | PI |
| ID: | PA260579 |
| Title: | Metabolic Sensitization of MUC13-Directed Terbium-161 Therapy in Pancreatic Ductal Adenocarcinoma |
| Funding Source: | Project Purple |
| Role: | PI |
| Title: | Targeting Metabolic-Epigenetic Control of DNA Repair to Overcome KEAP1-Mutant Lung Cancer Radioresistance |
| Funding Source: | United States Department of Defense |
| Role: | PI |
| ID: | LC260311 |
Selected Publications
Peer-Reviewed Articles
- Y Rai, M Hoseini-Ghahfarokhi, SJ Bright, WA Da Silva Brito, D Lee, MTF Reis, MD Wasley, LC Fru, M Salehpour, A Schori, A Alfassi, E Gebert, GO Sawakuchi. Radiobiological characterization of 60 keV quasi-monoenergetic convergent photons. Int J Radiat Oncol Biol Phys 26, 2026. e-Pub 2026. PMID: 42362067.
- Su, T, Yu, X, Hoseini-Ghahfarokhi, M, Flint, DB, Bright, SJ, Antunes, JI, Martinus, DK, Manandhar, M, Ben Kacem, M, Marinello, P, Pereira, EJ, Chiu, HS, Titt, U, Grosshans, DR, Schuemann, J, Willers, H, Paganetti, H, Sumazin, P, Sawakuchi, GO. Differentiation Stage Predicts Radiosensitivity in Mesenchymal-Like Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics 123(1):270-281, 2025. e-Pub 2025. PMID: 40180058.
- Schalck A, Tran T, Li J, Sei E, Bai S, Hu M, Lin J, Bright SJ, Reddick S, Yang F, Batra H, Contreras A, Raso MG, Stauder MC, Hoffman KE, Reddy JP, Nead KT, Smith BD, Sawakuchi GO, Woodward WA, Watowich SS, Litton JK, Bedrosian I, Mittendorf EA, Le-Petross H, Navin NE, Shaitelman SF. The impact of breast radiotherapy on the tumor genome and immune ecosystem. Cell Rep 44(5):115703, 2025. e-Pub 2025. PMID: 40378044.
- Flint, DB, Bright, SJ, McFadden, CH, Konishi, T, Martinus, DK, Manandhar, M, Ben Kacem, M, Bronk, LF, Sawakuchi, GO. An empirical model of carbon-ion relative biological effectiveness based on the linear correlation between radiosensitivity to photons and carbon ions. Physics in medicine and biology 69(24), 2024. e-Pub 2024. PMID: 39530708.
- Ben Kacem, M, Bright, SJ, Moran, E, Flint, DB, Martinus, DK, Turner, B, Qureshi, I, Kolachina, RV, Manandhar, M, Marinello, P, Shaitelman, SF, Sawakuchi, GO. PARP inhibition radiosensitizes BRCA1 wildtype and mutated breast cancer to proton therapy. Scientific reports 14(1), 2024. e-Pub 2024. PMID: 39730675.
- Bright SJ, Manandhar M, Flint DB, Kolachina R, Ben Kacem M, Martinus DK, Turner BX, Qureshi I, McFadden CH, Marinello PC, Shaitelman SF, Sawakuchi GO. ATR inhibition radiosensitizes cells through augmented DNA damage and G2 cell cycle arrest abrogation. JCI Insight 9(19), 2024. e-Pub 2024. PMID: 39235982.
- Bright SJ, Flint DB, Martinus DKJ, Turner BX, Manandhar M, Kacem MB, McFadden CH, Yap TA, Shaitelman SF, Sawakuchi GO. Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and Protons. Radiation Research 198(4), 2022. e-Pub 2022.
- Manandhar M, Bright SJ, Flint DB, Martinus DKJ, Kolachina RV, Kacem MB, Titt U, Martin TJ, Lee CL, Morrison K, Shaitelman SF, Sawakuchi GO. Effect of boron compounds on the biological effectiveness of proton therapy. Medical Physics 49(9), 2022. e-Pub 2022.
- Flint DB, Ruff CE, Bright SJ, Yepes P, Wang Q, Manandhar M, Kacem MB, Turner BX, Martinus DKJ, Shaitelman SF, Sawakuchi GO. An empirical model of proton RBE based on the linear correlation between x-ray and proton radiosensitivity. Medical Physics 49(9), 2022. e-Pub 2022.
- Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF. Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing. International Journal of Radiation Oncology-Biology-Physics 112(2):437-444, 2022. e-Pub 2022. PMID: 34582940.
- Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF. Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation. International Journal of Radiation Oncology-Biology-Physics 112(2):426-436, 2022. e-Pub 2022. PMID: 34610390.
- Flint DB, Bright SJ, McFadden CH, Konishi T, Ohsawa D, Turner B, Lin SH, Grosshans DR, Chiu HS, Sumazin P, Shaitelman SF, Sawakuchi GO. Cell Lines of the Same Anatomic Site and Histologic Type Show Large Variability in Intrinsic Radiosensitivity and Relative Biological Effectiveness to Protons and Carbon Ions. Medical Physics 48(6):3242-3261, 2021. e-Pub 2021. PMID: 33837540.
- Elbakrawy E, Kaur Bains S, Bright S, Al-Abedi R, Mayah A, Goodwin E, Kadhim M. Radiation-Induced Senescence Bystander Effect: The Role of Exosomes. Biology 9(8):191, 2020. e-Pub 2020. PMID: 32726907.
- McFadden CH, Rahmanian S, Flint DB, Bright SJ, Yoon DS, O'Brien DJ, Asaithamby A, Abdollahi A, Greilich S, Sawakuchi GO. Isolation of time-dependent DNA damage induced by energetic carbon ions and their fragments using fluorescent nuclear track detectors. Medical Physics 47(1), 2020. e-Pub 2020.
- Bright SJ, Flint DB, Chakraborty S, McFadden CH, Yoon DS, Bronk L, Titt U, Mohan R, Grosshans DR, Sumazin P, Shaitelman SF, Asaithamby A, Sawakuchi GO. Nonhomologous End Joining Is More Important Than Proton Linear Energy Transfer in Dictating Cell Death. International Journal of Radiation Oncology-Biology-Physics 105(5):1119-1125, 2019. e-Pub 2019. PMID: 31425731.
- Bains SK, Chapman K, Bright S, Senan A, Kadhim M, Slijepcevic P. Effects of Ionizing Radiation on Telomere Length and Telomerase Activity in Cultured Human Lens Epithelium Cells. International Journal of Radiation Biology 95(1):54-63, 2019. e-Pub 2019. PMID: 29667481.
- S Bright S, Kadhim M. The Future Impacts of Non-Targeted Effects. International Journal of Radiation Biology 94(8):727-736, 2018. e-Pub 2018. PMID: 29569509.
- Dalke C, Neff F, Bains SK, Bright S, Lord D, Reitmeir P, Rößler U, Samaga D, Unger K, Braselmann H, Wagner F, Greiter M, Gomolka M, Hornhardt S, Kunze S, Kempf SJ, Garrett L, Hölter SM, Wurst W, Rosemann M, Azimzadeh O, Tapio S, Aubele M, Theis F, Hoeschen C, Slijepcevic P, Kadhim M, Atkinson M, Zitzelsberger H, Kulka U, Graw J. Lifetime Study in Mice After Acute Low-Dose Ionizing Radiation: A Multifactorial Study with Special Focus on Cataract Risk. Radiation and Environmental Biophysics 57(2):99-113, 2018. e-Pub 2018. PMID: 29327260.
- Szatmári T, Kis D, Bogdándi EN, Benedek A, Bright S, Bowler D, Persa E, Kis E, Balogh A, Naszályi LN, Kadhim M, Sáfrány G, Lumniczky K. Extracellular Vesicles Mediate Radiation-Induced Systemic Bystander Signals in the Bone Marrow and Spleen. Frontiers in Immunology 8(MAR):347, 2017. e-Pub 2017. PMID: 28396668.
- Al-Mayah AH, Bright SJ, Bowler DA, Slijepcevic P, Goodwin E, Kadhim MA. Exosome-Mediated Telomere Instability in Human Breast Epithelial Cancer Cells after X Irradiation. Radiation Research 187(1):98-106, 2017. e-Pub 2017. PMID: 27959588.
- Ainsbury EA, Barnard S, Bright S, Dalke C, Jarrin M, Kunze S, Tanner R, Dynlacht JR, Quinlan RA, Graw J, Kadhim M, Hamada N. Ionizing Radiation Induced Cataracts: Recent Biological and Mechanistic Developments and Perspectives for Future Research. Mutation Research 770(Pt. B):238-261, 2016. e-Pub 2016. PMID: 27919334.
- Al-Mayah A, Bright S, Chapman K, Irons S, Luo P, Carter D, Goodwin E, Kadhim M. The Non-Targeted Effects of Radiation are Perpetuated by Exosomes. Mutation Research 772:38-45, 2015. e-Pub 2015. PMID: 25772109.
Review Articles
- Coll, RP, Bright, SJ, Martinus, DK, Georgiou, DK, Sawakuchi, GO, Manning, HC. Alpha Particle–Emitting Radiopharmaceuticals as Cancer Therapy. Molecular Imaging and Biology 25(6):991-1019, 2023. e-Pub 2023. PMID: 37845582.
Patient Reviews
CV information above last modified July 22, 2026